Prophylactic Trimethoprim-Sulfamethoxazole for Allogeneic Hematopoietic Stem Cell Transplant Recipients During the Pre-engraftment Period [0.03%]
异基因造血干细胞移植患者植入前期的磺胺甲基异恶唑-甲氧苄氨嘧啶预防用药研究
Kelly J Gaffney,Theresa A Urban,Mariana Lucena et al.
Kelly J Gaffney et al.
Background: Our institution has used trimethoprim-sulfamethoxazole (TMP-SMX) as the antibacterial agent of choice for infection prophylaxis during the pre-engraftment period in the allogeneic transplant (allo-HCT) populat...
Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma [0.03%]
多发性骨髓瘤患者脊柱压迫相关住院的种族差异
Samer Al Hadidi,Deepa Dongarwar,Carolina Schinke et al.
Samer Al Hadidi et al.
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma [0.03%]
RO7297089（一种抗BCMA/CD16a双特异性抗体）在复发性多发性骨髓瘤患者中进行的安全性和药代动力学一期研究
Torben Plesner,Simon J Harrison,Hang Quach et al.
Torben Plesner et al.
Introduction: This phase 1 trial assessed the safety, pharmacokinetics, and preliminary antitumor activity of RO7297089, an anti-BCMA/CD16a bispecific antibody. ...
Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia [0.03%]
T细胞急性淋巴细胞白血病异基因造血干细胞移植后阿扎胞苷联合维奈托克巩固治疗
Mona Ali Hassan,Nour Moukalled,Jean El Cheikh et al.
Mona Ali Hassan et al.
Health Disparities Experienced by Hispanic Americans with Multiple Myeloma: A Systematic Review [0.03%]
西班牙裔美国人患多发性骨髓瘤所经历的健康差异：系统评价
Andrea Anampa-Guzmán,Sara Taveras Alam,Inas Abuali et al.
Andrea Anampa-Guzmán et al.
Health disparities in multiple myeloma (MM) disproportionately affect minorities. Characterization of health disparities encountered by Hispanic Americans with MM is necessary to identify gaps and inform future strategies to eliminate them....
The Ten Most Common Questions on Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients [0.03%]
血液干细胞移植患者巨细胞病毒感染的十个常见问题
Johnny Zakhour,Fatima Allaw,Sara F Haddad et al.
Johnny Zakhour et al.
With the rising number of patients undergoing hematopoietic stem cell transplantation (HSCT), clinicians are more likely to encounter infectious complications in immunocompromised hosts, particularly cytomegalovirus (CMV) infection. Besides...
How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms [0.03%]
我如何管理不适用于移植的骨髓增生异常综合征患者
Carmelo Gurnari,Zhuoer Xie,Amer M Zeidan
Carmelo Gurnari
Myelodysplastic neoplasms, formerly known as myelodysplastic syndromes (MDS), represent a group of clonal disorders characterized by a high degree of clinical and molecular heterogeneity, and an invariable tendency to progress to acute myel...
Effects of Erythrocytapheresis Procedures on Delayed Bone Marrow Conversion in Sickle Cell Disease [0.03%]
红细胞单采术对镰状细胞病延迟骨髓转换的影响
Emily Popham,Karen Moeller,Ashok Raj
Emily Popham
The imaging appearances of the skeletal system have been well documented in sickle cell disease (SCD) but there is limited information about the impact of SCD treatments on skeletal abnormalities. We present two patients with SCD maintained...
Mohamad Mohty,Robert A Kyle
Mohamad Mohty
Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study [0.03%]
伊布替尼治疗慢性淋巴细胞白血病在常规临床实践中的有效性和安全性：比利时伊布替尼真实世界数据（BiRD）研究的3年随访结果分析
Ann Janssens,Zwi N Berneman,Fritz Offner et al.
Ann Janssens et al.
The multicenter observational BiRD study investigated the real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia (WM) in Belgium....